All In Biotech

Drug Trial Radar · NCT06533540

Safety Study of TPX-121 on Nasolabial Folds

A Single-center, Single Group, Dose Escalation, Phase 1 Clinical Trial to Investigate the Safety of TPX-121 in Subjects With Moderate-to-Extreme Nasolabial Folds

Last checked: Nov 20, 2026Latest source record: Jul 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

18

Planned (sponsor's estimate)

Start

Dec 11, 2024

Primary completion

Mar 2026

Study completion Dec 2026

Sponsor

Lead sponsor
Tego Science, Inc.Industry
Sponsor type
Industry
First posted
Aug 1, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 19 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Nasolabial folds augmentation is possible through dermal filler and botulinum toxin, however, safety issues are existed as well as efficacy. Therefore, there is a need for a safer procedure for nasolabial folds correction. This study (Project No. TPX-121) assesses the safety of allogeneic fibroblasts (TPX-115) on nasolabial folds. The safety endpoint is dose-limiting toxicity (DLT). In addition, exploratory endpoints are the improvement of nasolabial folds in Wrinkle Severity Rating Scale (WSRS) at week 4 and 12, change in WSRS and Wrinkle Severity Scale (WSS) at week 4 and 12, and overall appearance improvement rate in Global Aesthetic Improvement Scale (GAIS) at week 4 and 12.

Conditions

  • Nasolabial Fold, Hypoplastic

Interventions

  • TPX-115(allogeneic fibroblasts)Biological

    Intradermal injection of TPX-115(allogeneic fibroblasts)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose-limiting toxicityTime frame: Week 4

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Kyungpook National University, School of Medicine

    Daegu, Jung-gu, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.